Baseline characteristics of participants presenting with or without peripheral artery disease (PAD)...

10
Baseline characteristics of participants presenting with or without peripheral artery disease (PAD) Heart Protection Study Group J Vasc Surg 2007;45:645-54

description

Absolute effects of simvastatin allocation on 5-year rates of first major vascular events among participants subdivided by prior PAD Heart Protection Study Group J Vasc Surg 2007;45:645-54

Transcript of Baseline characteristics of participants presenting with or without peripheral artery disease (PAD)...

Page 1: Baseline characteristics of participants presenting with or without peripheral artery disease (PAD) Heart Protection Study Group J Vasc Surg 2007;45:645-54.

Baseline characteristics of participants presenting with or without peripheral artery disease (PAD)

Heart Protection Study Group J Vasc Surg 2007;45:645-54

Page 2: Baseline characteristics of participants presenting with or without peripheral artery disease (PAD) Heart Protection Study Group J Vasc Surg 2007;45:645-54.

Effects of simvastatin allocation on first major coronary event, stroke, or revascularization in participants

presenting with or without peripheral artery disease

Heart Protection Study Group J Vasc Surg 2007;45:645-54

Page 3: Baseline characteristics of participants presenting with or without peripheral artery disease (PAD) Heart Protection Study Group J Vasc Surg 2007;45:645-54.

Absolute effects of simvastatin allocation on 5-year rates of first major vascular events among participants subdivided by prior PAD

Heart Protection Study Group J Vasc Surg 2007;45:645-54

Page 4: Baseline characteristics of participants presenting with or without peripheral artery disease (PAD) Heart Protection Study Group J Vasc Surg 2007;45:645-54.

Effects of simvastatin allocation on major vascular events in prior disease subgroups

Heart Protection Study Group J Vasc Surg 2007;45:645-54

Page 5: Baseline characteristics of participants presenting with or without peripheral artery disease (PAD) Heart Protection Study Group J Vasc Surg 2007;45:645-54.

Effects of simvastatin allocation on first major vascular event in participants with or without PAD subdivided by other presenting features

Heart Protection Study Group J Vasc Surg 2007;45:645-54

Page 6: Baseline characteristics of participants presenting with or without peripheral artery disease (PAD) Heart Protection Study Group J Vasc Surg 2007;45:645-54.

Effects of simvastatin allocation on first and all major vascular events in participants with or without PAD

Heart Protection Study Group J Vasc Surg 2007;45:645-54

Page 7: Baseline characteristics of participants presenting with or without peripheral artery disease (PAD) Heart Protection Study Group J Vasc Surg 2007;45:645-54.

Effects of simvastatin allocation on first peripheral vascular event subdivided by presenting features

Heart Protection Study Group J Vasc Surg 2007;45:645-54

Page 8: Baseline characteristics of participants presenting with or without peripheral artery disease (PAD) Heart Protection Study Group J Vasc Surg 2007;45:645-54.

Average use of statin (study or non-study), and average plasma LDL cholesterol concentrations, during follow-up. Table online only

Heart Protection Study Group J Vasc Surg 2007;45:645-54

Page 9: Baseline characteristics of participants presenting with or without peripheral artery disease (PAD) Heart Protection Study Group J Vasc Surg 2007;45:645-54.

DISCUSSION

Heart Protection Study Group J Vasc Surg 2007;45:645-54

Page 10: Baseline characteristics of participants presenting with or without peripheral artery disease (PAD) Heart Protection Study Group J Vasc Surg 2007;45:645-54.

INVITED COMMENTARYWilliam R. Hiatt

Heart Protection Study Group J Vasc Surg 2007;45:645-54